CN101757409A - Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis - Google Patents
Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis Download PDFInfo
- Publication number
- CN101757409A CN101757409A CN200810079621A CN200810079621A CN101757409A CN 101757409 A CN101757409 A CN 101757409A CN 200810079621 A CN200810079621 A CN 200810079621A CN 200810079621 A CN200810079621 A CN 200810079621A CN 101757409 A CN101757409 A CN 101757409A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine composition
- chinese medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a traditional Chinese medicine composition in the preparation of medicines for treating silicosis. The medicine composition comprises 12 types of traditional Chinese herbs of ginseng, radix ophiopogonis, dogwood and the like. Clinical tests prove that the medicine composition used for treating the silicosis can obviously ameliorate clinical symptoms and the lung function and has favorable curative effect.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment pneumosilicosis medicine.Belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Pneumosilicosis (silicosis) is one type the most serious in the pneumoconiosis, because long-term the suction contained free silicon dioxide (Si0
2) dust cause.There is nodositas fibrosis widely in pulmonary, influences pulmonary function, disability when serious.
In general, contain the dust of free silicon dioxide more than 80%, often cause that in pulmonary typical diffusivity collagen fiber based on tuberosity change, disease progression is very fast, and easily merges.Free silicon dioxide is lower than at 80% o'clock, and pathological changes is the typical case not too, and disease progression is slower.Be lower than at 10% o'clock, cause mainly that then interstitial fibers changes, develop slowlyer, be listed as other pneumoconiosis.
Contain the very high dust of free silicon dioxide in a large number and suck in the lung, often can't in time and fully remove by respiratory tract.Though do not occur pneumosilicosis sign sometimes, after pneumosilicosis appears in the several years again, often be called " delayed silicosis " in disengaging work; Even early stage silicotic breaks away from dust work, the state of an illness also can continue development, and as no complication, the patient can be survived the long period, but normal disability.
The basic lesion of pneumosilicosis is to form silicon tuberosity and the extensive fibrosis of interstitial lung, and the silicotic generally in early days can be asymptomatic or symptom is not obvious, and along with pathological development, symptom increases, and mainly shows as follows: cough, cough up phlegm, chest pain, uncomfortable in chest, out of breath.The early stage normal no abnormal discovery of silicotic's health check-up.Because tuberosity merges, lung tissue is shunk, and trachea displacement and the turbid sound of kowtowing can be arranged during the severe pneumosilicosis.
Diagnosis should foundation: dust contact history, the detailed occupational history of patient and in the past health condition, clinical symptoms, sign and X ray examination, with the work post workman previously and at present incidence make a definite diagnosis.
Through the X ray examination, pneumosilicosis diagnosis at present except that above-mentioned foundation, mainly shows according to X line rabat.China has announced " pneumoconiosis diagnostic criteria and treatment principle " in December, 1986, and wherein pneumoconiosis X radiodiagnosis x standard is applicable to the various pneumoconiosis that country is legal, and its concrete standard is as follows: do not have pneumoconiosis (code name 0) 1.; 2. first phase pneumoconiosis (code name I); 3. the second stage of pneumoconiosis (code name II); 4. three phase pneumoconiosis (code name III).
The tetrandrine of clinical practice, hydroxyl piperaquine phosphate, oxypovidinum and four kinds of medicines of aluminium citrate, they act on respectively, and pneumosilicosis takes place, the different links of development, cutter system is not clear fully as yet really but treat pneumosilicosis.
Patent ZL02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof, and present patent application quotes in full the content that patent ZL02146572.X is put down in writing.The application of unexposed this pharmaceutical composition of this patent in preparation treatment pneumosilicosis medicine.
Summary of the invention
The purpose of this invention is to provide the application of a kind of Chinese medicine composition in preparation treatment pneumosilicosis medicine;
Described Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of crude drug is preferably in the described Chinese medicine composition:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the described Chinese medicine composition:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the described Chinese medicine composition:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and is standby;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, and is standby;
E) with step b) and d) merging of gained extracting solution, reclaim ethanol, be condensed into extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
In the application of the present invention, described Chinese medicinal composition preparation dosage form is a capsule, tablet, granule, powder or oral liquid, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Preferably, the present invention uses the preparation method of described capsule and is:
A) people participates in 8 times of amount 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into 80 order fine powders;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and merge extractive liquid, filters, and reclaims ethanol;
C) TUBIECHONG is ground into 80 order fine powders;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of amount decoctions of water 2 times, merge extractive liquid,, filter, the extracting solution merging with the step b) gained is condensed into extractum, add step c) gained fine powder, oven dry is ground into 80 order fine powders, adds step a) gained fine powder, mixing, promptly encapsulated.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
The present invention uses the compound preparation that described Chinese medicine composition is made up of Radix Ginseng, Radix Ophiopogonis, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos, Fructus Corni, Herba Taxilli etc., has the Comprehensive Treatment effect of supplementing QI and nourishing YIN, promoting blood circulation to remove obstruction in the collateral, clearing away heart-fire for tranquillization.Prove that by clinical trial this pharmaceutical composition is applied to the silicotic, obtained the remarkable result of total effective rate 95%, can be used for the treatment of pneumosilicosis.
The specific embodiment
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into fine powder, and is standby;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, and is standby;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is standby;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and filtrate merges with step b) gained extracting solution, and concentrated extractum is standby;
E) with step d) gained extractum, add the fine drug powder oven dry of step c) gained, be ground into fine powder, add step a) gained fine drug powder, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Embodiment 2
Prescription:
Radix Ginseng 45g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 225g Semen Ziziphi Spinosae (parched) 186g
Herba Taxilli 186g Radix Paeoniae Rubra 89g Radix Et Rhizoma Nardostachyos 45g Eupolyphaga Seu Steleophaga 35g Rhizoma Coptidis 45g
Fructus Schisandrae Sphenantherae 67g Os Draconis 149g.
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into fine powder, and is standby;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, and is standby;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is standby;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and filtrate merges with step b) gained extracting solution, and concentrated extractum is standby;
E) with step d) gained extractum, add the fine drug powder oven dry of step c) gained, be ground into fine powder, add step a) gained fine drug powder, mixing, preparation process is pressed into 1000 routinely.
Usage and consumption: oral.One time 2～4,3 times on the one.
Embodiment 3
Prescription:
Radix Ginseng 175g 192g Radix Ophiopogonis Fructus Corni 421g Radix Salviae Miltiorrhizae 440g Semen Ziziphi Spinosae (parched) 395g
Herba Taxilli 396g Radix Paeoniae Rubra 188g Eupolyphaga Seu Steleophaga 98g Radix Et Rhizoma Nardostachyos 188g Rhizoma Coptidis 85g
Fructus Schisandrae Sphenantherae 147g Os Draconis 278g.
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into fine powder, and is standby;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, and is standby;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is standby;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and filtrate merges with step b) gained extracting solution, and concentrated extractum is standby;
E) with step d) gained extractum, add the fine drug powder oven dry of step c) gained, be ground into fine powder, add step a) gained fine drug powder, mixing is made 1000 bags of granules according to conventional formulation.
Usage and consumption: oral.One time 2～4 bags, 3 times on the one.
Essence for a better understanding of the present invention in " treatment pneumosilicosis " result of the test, illustrates its new purposes at pharmaceutical field below by this pharmaceutical composition of clinical observation.
Experimental example:
1 data and method
1.1 the whole cases of physical data all are selected from 2004.5-2007.12 Hebei Yi Ling hospital ward patient, amount to 70 examples, and the patient is divided into treatment group and matched group at random.40 examples are organized in treatment, are the male, age 32-63 year, average 47.5 years old, pneumosilicosis course of disease 9-15, average 12 years.Merge emphysema 12 examples, pulmonary heart disease 5 examples.Matched group 30 examples are the male, age 38-67 year, average 52.5 years old, pneumosilicosis course of disease 10-17, average 13.5 years.Merge emphysema 5 examples, pulmonary heart disease 2 examples.Two groups by statistics, and two groups at aspect there was no significant differences (P＞0.05) such as sex, age, the course of disease, the state of an illness, has comparability.
1.2 case is selected inclusion criteria: (1) meets People's Republic of China's state health standards (GB5906-86) " diagnostic standard of silicosis and treatment principle ", makes a definite diagnosis through X line chest film inspection; (2) belong to serious symptom pneumosilicosis (III phase pneumosilicosis) patient.
1.3 Therapeutic Method matched group infection cefotaxime sodium injection 2g, intravenous injection, 2 times/day.Aminophylline is obviously share in asthma; Heart rate adds the usefulness Folium Digitalis Purpureae soon, the mucosolvan sheet is oral.The treatment group adds on the matched group basis uses medicine capsule of the present invention, and 4/time, 3 times/day.4 weeks were 1 course of treatment.
1.4 observation index: pulmonary function (vital capacity (VC), forced vital capacity (FVC) and 1 forced expiratory volume in second (FEV)) relatively.
1.5 curative effect determinate standard: formulate according to the tcm internal medicine disease diagnosis criterion of therapeutical effect that State Administration of Traditional Chinese Medicine formulates.Produce effects: pant and other transference cure, lab testing is clearly better; Effectively: pant and other symptom improvement, lab testing has improvement; Invalid: cardinal symptom does not have improvement or increases the weight of.
1.6 statistical procedures adopts the SPSS13.0 statistical software to carry out date processing, measurement data is with mean ± standard deviation
The t check is adopted in expression, and enumeration data adopts x
2Check.
2 results
2.1 clinical efficacy more by statistics, treatment group patient total effective rate is apparently higher than matched group (P＜0.05).The results are shown in Table 1.
Table 1 liang group patient clinical efficacy is (%) relatively
Annotate: * and # be x relatively
2=11.37, P＜0.05.
2.2 lung function index changes by statistics before and after the treatment, the treatment group is compared with matched group, and VC, FVC and FEV all obviously increase (P＜0.05).The results are shown in Table 2.
The comparison of table 2 liang group patient pulmonary function
Annotate: * and # be P＜0.05 relatively.
3 conclusions
This research adds Drug therapy of the present invention on the basis of doctor trained in Western medicine conventional therapy, improving clinical efficacy, improving aspect such as pulmonary function and all be better than simple western medical treatment, confirm that fully medicine of the present invention has significant curative effect to the serious symptom pneumosilicosis.
Claims (7)
1. the application of a Chinese medicine composition, this Chinese medicine composition is made by following bulk drugs: Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part, it is characterized in that the application of described Chinese medicine composition in preparation treatment pneumosilicosis medicine.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. as the arbitrary described application of claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and is standby;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, and is standby;
E) with step b) and d) merging of gained extracting solution, reclaim ethanol, be condensed into extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. as each described application among the claim 1-4, it is characterized in that the preparation formulation of described Chinese medicine composition is capsule, tablet, granule, powder or oral liquid.
7. application as claimed in claim 6 is characterized in that, described capsule is made by following steps:
A) people participates in 8 times of amount 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into 80 order fine powders;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and merge extractive liquid, filters, and reclaims ethanol;
C) TUBIECHONG is ground into 80 order fine powders;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of amount decoctions of water 2 times, merge extractive liquid,, filter, the extracting solution merging with the step b) gained is condensed into extractum, add step c) gained fine powder, oven dry is ground into 80 order fine powders, adds step a) gained fine powder, mixing, promptly encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100796218A CN101757409B (en) | 2008-10-24 | 2008-10-24 | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100796218A CN101757409B (en) | 2008-10-24 | 2008-10-24 | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101757409A true CN101757409A (en) | 2010-06-30 |
| CN101757409B CN101757409B (en) | 2013-02-27 |
Family
ID=42488893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100796218A Active CN101757409B (en) | 2008-10-24 | 2008-10-24 | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101757409B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824568A (en) * | 2011-06-19 | 2012-12-19 | 孙斌 | Traditional Chinese medicine for treating silicosis |
| CN102872190A (en) * | 2012-09-10 | 2013-01-16 | 顾康春 | Chinese traditional medicine for treating silicosis |
| CN103071047A (en) * | 2013-02-05 | 2013-05-01 | 许海涛 | Decoction for treating silicosis and preparation method thereof |
| CN104383014A (en) * | 2014-11-28 | 2015-03-04 | 朱蕾 | Medicinal composition for treating pneumoconiosis and method for preparing same |
| CN104887956A (en) * | 2015-06-09 | 2015-09-09 | 国家电网公司 | Traditional Chinese medicine preparation for treating electric power industry occupational disease, namely pneumoconiosis |
| EP3270929A4 (en) * | 2015-03-17 | 2018-03-14 | Lee, Sheau-Long | Use of ginsenoside m1 for preventing or treating silicosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632783B (en) * | 2008-07-21 | 2013-01-02 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale |
-
2008
- 2008-10-24 CN CN2008100796218A patent/CN101757409B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824568A (en) * | 2011-06-19 | 2012-12-19 | 孙斌 | Traditional Chinese medicine for treating silicosis |
| CN102824568B (en) * | 2011-06-19 | 2014-11-05 | 师厚刚 | Traditional Chinese medicine for treating silicosis |
| CN102872190A (en) * | 2012-09-10 | 2013-01-16 | 顾康春 | Chinese traditional medicine for treating silicosis |
| CN102872190B (en) * | 2012-09-10 | 2014-08-20 | 顾康春 | Chinese traditional medicine for treating silicosis |
| CN103071047A (en) * | 2013-02-05 | 2013-05-01 | 许海涛 | Decoction for treating silicosis and preparation method thereof |
| CN104383014A (en) * | 2014-11-28 | 2015-03-04 | 朱蕾 | Medicinal composition for treating pneumoconiosis and method for preparing same |
| EP3270929A4 (en) * | 2015-03-17 | 2018-03-14 | Lee, Sheau-Long | Use of ginsenoside m1 for preventing or treating silicosis |
| CN104887956A (en) * | 2015-06-09 | 2015-09-09 | 国家电网公司 | Traditional Chinese medicine preparation for treating electric power industry occupational disease, namely pneumoconiosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101757409B (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101757409B (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis | |
| CN101632781B (en) | Application of Chinese medicinal composition in preparing medicament for treating xerophthalmia | |
| CN102283951B (en) | Chinese medicinal composition for treating anaphylactoid purpura and thrombocytopenic purpura | |
| CN101406613B (en) | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN102145050A (en) | Application of traditional Chinese medicine composition for preparing drugs for preventing and treating post percutaneous coronary intervention (PCI) no-reflow | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101590173B (en) | Application of traditional Chinese medicine composition in preparing medicine for treating hypertensive intracerebral hemorrhage | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN101607058B (en) | Application of Chinese medicinal composition in preparing medicament for treating chronic nephritis | |
| CN101632784B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute myocardial infarction | |
| CN101559114A (en) | Application of traditional Chinese medicine composition in preparing antihypoxic | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN103623207A (en) | Applications of traditional Chinese medicine composition in preparation of medicines used for treating chronic heart failure together with arrhythmia | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN102380030B (en) | TCM composition applied to preparation of medication for treating siriasis | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN101732469A (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN106668601B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease phlegm-heat syndrome and preparation method and application thereof | |
| CN106266307B (en) | Ant bear gall pill and its preparation method and application | |
| CN101653549A (en) | Chinese medicinal composition in preparation of medicament for treating congestive heart-failure | |
| CN101411813B (en) | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |